Year: 2015
Type: review
Abstract: Epstein–Barr virus, a ubiquitous human herpesvirus, can induce both lytic and latent infections that result in a variety of human diseases, including lymphoproliferative disorders. The oncogenic potential of Epstein–Barr virus is related to its ability to infect and transform B lymphocytes into continuously proliferating lymphoblastoid cells. However, Epstein–Barr virus has also been implicated in the development of T/natural killer cell lymphoproliferative diseases. Epstein–Barr virus encodes a series of products that mimic several growth, transcription and anti-apoptotic factors, thus usurping control of pathways that regulate diverse homeostatic cellular functions and the microenvironment. However, the exact mechanism by which Epstein–Barr virus promotes oncogenesis and inflammatory lesion development remains unclear. Epstein–Barr virus-associated T/natural killer cell lymphoproliferative diseases often have overlapping clinical symptoms as well as histologic and immunophenotypic features because both lymphoid cell types derive from a common precursor. Accurate classification of Epstein–Barr virus-associated T/natural killer cell lymphoproliferative diseases is a prerequisite for appropriate clinical management. Currently, the treatment of most T/natural killer cell lymphoproliferative diseases is less than satisfactory. Novel and targeted therapies are strongly required to satisfy clinical demands. This review describes our current knowledge of the genetics, oncogenesis, biology, diagnosis and treatment of Epstein–Barr virus-associated T/natural killer cell lymphoproliferative diseases. The role of Epstein-Barr virus (EBV) in the proliferation of some white blood cells of the immune system is complex and needs further study. EBV causes glandular fever in humans and is also associated with a range of lymphoproliferative disorders, especially blood cancers, in which white blood cells multiply excessively. Qingqing Cai of Sun Yat-sen University in China, and colleagues in the USA have reviewed the role of EBV in the proliferation of T-cells and natural killer cells, which promotes inflammatory lesions and oncogenesis. As both types of white cell are derived from a common precursor, their activities and disorders share many characteristics. The authors consider the genetics, biology, diagnosis, and treatment of several specific lymphoproliferative disorders associated with EBV. Existing treatment options are unsatisfactory and new approaches to therapy are required.
DOI: 10.1038/emm.2014.105
Authors: Qingqing Cai, Kailin Chen, Ken H Young
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,490
Funders: Gilead Sciences, National Natural Science Foundation of China, Sun Yat-sen University, Natural Science Foundation of Guangdong Province, National Institutes of Health, University of Texas MD Anderson Cancer Center, Science and Technology Planning Project of Guangdong Province, Sun Yat-sen University Cancer Center, National Cancer Institute
Awards: G4215535582, Deep Sequencing of Small Regulatory RNAs in Diffuse Large B cell Lymphoma, M. D. Anderson Cancer Center SPORE in Multiple Myeloma, G5205017604, miR-374b靶向AKT诱导T细胞淋巴瘤细胞凋亡的研究, G6330936, G7891028497, Convergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental Co, G8122636988, G8492985506, UT M.D. Anderson Cancer Center Lymphoma SPORE, G880294081, G9000061078
OpenAlex ID: W2029072078